Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$41.48 USD

41.48
13,665,302

+0.60 (1.47%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $41.48 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Mark Vickery headshot

Top Analyst Reports for NVIDIA, Bristol-Myers Squibb & ICICI Bank

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Bristol-Myers Squibb Company (BMY) and ICICI Bank Limited (IBN).

Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?

by Zacks Equity Research

Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.

Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.

Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review

by Zacks Equity Research

Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.

FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug

by Zacks Equity Research

The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.

Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation

by Zacks Equity Research

Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.

Mirati's (MRTX) Sitravatinib Fails Lung Cancer Study, Stock Down 8%

by Zacks Equity Research

Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.

Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results

by Zacks Equity Research

Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.

Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y

by Zacks Equity Research

Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.

Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up

by Zacks Equity Research

Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development is on track.

Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up

by Zacks Equity Research

Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in focus.

Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.

Pfizer (PFE) Q1 Earnings Beat, COVID Jab Sales Down as Expected

by Zacks Equity Research

Pfizer (PFE) beats estimates for Q1 earnings and sales. Revenues from its COVID-19 vaccine, Comirnaty declined, as expected.

Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt Sales

by Zacks Equity Research

Bristol-Myers' (BMY) first-quarter 2023 earnings top estimates, while sales missed the same and declined year over year due to generic erosion for the oncology drug Revlimid.

Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bristol Myers Squibb (BMY) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 3.54% and 2.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Markets Continue Steady Slide; META, EBAY Beat Q1 Earnings

by Mark Vickery

Except the Nasdaq, which snapped a two-day losing streak and was the only major index in the green all day.

Ahan Chakraborty headshot

Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More

by Ahan Chakraborty

Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.

Should You Buy Bristol Myers Squibb (BMY) Ahead of Earnings?

by Zacks Equity Research

Bristol Myers Squibb (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx

by Zacks Equity Research

Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx are included in this Analyst Blog.

Sheraz Mian headshot

Q1 Earnings Scorecard and Fresh Analyst Reports for Bristol-Myers, Medtronic & Altria Group

by Sheraz Mian

Q1 Earnings Season Scorecard is included in today's Research Daily in addition to new research reports on Bristol-Myers (BMY), Medtronic(MDT) and Altria Group (MO).

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Bristol-Myers (BMY) to Report Q1 Earnings: What+'s in Store?

by Zacks Equity Research

Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q1 results.

Earnings Preview: Vertex Pharmaceuticals (VRTX) Q1 Earnings Expected to Decline

by Zacks Equity Research

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.